Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mithat Gönen

Showing results (1-10 of 323) with videos related to

Pageof 33
Sort By:
Contemporary Clinical Trials|April 20, 2005
A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trialsMithat Gönen
Gastrointestinal Cancer Research : GCR|May 23, 2009
Statistical aspects of gene signatures and molecular targetsMithat Gönen
Methods in Molecular Biology (Clifton, N.J.)|July 24, 2010
The Bayesian t-test and beyondMithat Gönen
Academic Radiology|May 7, 2013
Mixtures of receiver operating characteristic curvesMithat Gönen
Controlled Clinical Trials|July 17, 2003
Planning for subgroup analysis: a case study of treatment-marker interaction in metastatic colorectal cancerMithat Gönen
Biometrics|July 1, 2011
Optimal Bayesian enrichment: a view from the closetMithat Gönen
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 18, 2011
Bias, biostatistics, and prognostic factorsMithat Gönen
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|March 4, 2014
[Bias, biostatistics, and prognostic factors]Mithat Gönen
Clinical Trials (London, England)|June 17, 2009
Bayesian clinical trials: no more excusesMithat Gönen
Statistics in Medicine|July 6, 2004
Sample size and power for McNemar's test with clustered dataMithat Gönen
Pageof 33

Showing results (1-10 of 323) with videos related to

Sort By:
Pageof 33
Contemporary Clinical Trials|April 20, 2005
A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trialsMithat Gönen
Gastrointestinal Cancer Research : GCR|May 23, 2009
Statistical aspects of gene signatures and molecular targetsMithat Gönen
Methods in Molecular Biology (Clifton, N.J.)|July 24, 2010
The Bayesian t-test and beyondMithat Gönen
Academic Radiology|May 7, 2013
Mixtures of receiver operating characteristic curvesMithat Gönen
Controlled Clinical Trials|July 17, 2003
Planning for subgroup analysis: a case study of treatment-marker interaction in metastatic colorectal cancerMithat Gönen
Biometrics|July 1, 2011
Optimal Bayesian enrichment: a view from the closetMithat Gönen
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 18, 2011
Bias, biostatistics, and prognostic factorsMithat Gönen
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|March 4, 2014
[Bias, biostatistics, and prognostic factors]Mithat Gönen
Clinical Trials (London, England)|June 17, 2009
Bayesian clinical trials: no more excusesMithat Gönen
Statistics in Medicine|July 6, 2004
Sample size and power for McNemar's test with clustered dataMithat Gönen
Pageof 33